Clinical Advances in Idiopathic Pulmonary Fibrosis: New Treatment Goals and Strategies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals

Idiopathic pulmonary fibrosis (IPF) is a lung disease that results from the formation of scar tissue deep inside the lungs and is the most common of the idiopathic interstitial pneumonias. IPF is a devastating disease associated with irreversible destruction of the lung as the scarring gets progressively worse which makes it difficult for patients to breathe as well as keep adequate levels of oxygen in the bloodstream. The condition is more common in men than in women, and its frequency increases with age between 40 and 70 years. IPF typically has a poor prognosis and the median survival rate is less than four years or fewer from diagnosis. Most patients with IPF present with a gradual onset, which makes it difficult to diagnosis early. Healthcare professionals are constantly looking at ways to diagnosis the disease much earlier to improve outcomes. It must start with the elicitation of a thorough and extensive medical history that should include review of symptoms or signs suggestive of a systemic disorder, occupational and environmental exposures, use of medications and drugs, and family medical history. Patients may also complain of paroxysmal dry cough, shortness of breath, and fatigue. Despite a growing prevalence, patients with IPF continue to suffer delays in diagnosis which can limit treatment options, as well as increase costs, reduce patient quality of life, and impact survival.

Upon completion of this activity, participants will be able to:

  • Assess the recent advances in the genetics of pulmonary fibrosis pathogenesis and how the information can be used to improve outcomes

  • Review the early signs and symptoms of IPF, as well as the ATS/ERS guidelines, to create an early and accurate diagnosis

  • Analyze the latest clinical evidence for the safety and efficacy of current and emerging pharmacotherapies

  • Explore guideline recommendations and clinical studies for emerging treatments, including monotherapy and combination therapy, to identify personalized treatment approaches for patients with IPF

  • Evaluate the impact of IPF on patient’s quality of life and strategies to better understand the caregiver’s engagement in the patient’s care

Faculty: David J Lederer, MD, MS
Associate Professor
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center


Dr. Lederer serves on an advisory board for Fibrogen, Global Blood Therapeutics and Sanofi Genzyme. He serves as a consultant for Galapagos, Roche and Veracyte. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue